Pfizer has reached an agreement to acquire the Sanofi-Aventis worldwide rights to inhaled human insulin for $1.3 billion. Pfizer intends to market the drug under the trade name Exubera. The two companies were previously in a worldwide alliance to co-develop, co-promote and co-manufacture Exubera. Also, Pfizer will acquire the insulin production facilities located in Frankfurt, Germany, previously jointly owned by the two companies. Exubera is a fast-acting dry powder formulation of human in...